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Abstract
Background: Pre-existing conditions interfere with cancer diagnosis by offering diagnostic 
alternatives, competing for clinical attention or through patient surveillance.
Objective: To investigate associations between oesophagogastric cancer stage and pre-existing 
conditions.
Methods: Retrospective cohort study using Clinical Practice Research Datalink (CPRD) data, with 
English cancer registry linkage. Participants aged ≥40  years had consulted primary care in the 
year before their incident diagnosis of oesophagogastric cancer in 01/01/2010–31/12/2015. CPRD 
records pre-diagnosis were searched for codes denoting clinical features of oesophagogastric 
cancer and for pre-existing conditions, including those providing plausible diagnostic alternatives 
for those features. Logistic regression analysed associations between stage and multimorbidity 
(≥2 conditions; reference category: no multimorbidity) and having ‘diagnostic alternative(s)’, 
controlling for age, sex, deprivation and cancer site.
Results: Of 2444 participants provided, 695 (28%) were excluded for missing stage, leaving 1749 
for analysis (1265/1749, 72.3% had advanced-stage disease). Multimorbidity was associated with 
stage [odds ratio 0.63, 95% confidence interval (CI) 0.47–0.85, P = 0.002], with moderate evidence 
of an interaction term with sex (1.76, 1.08–2.86, P  =  0.024). There was no association between 
alternative explanations and stage (odds ratio 1.18, 95% CI 0.87–1.60, P = 0.278).
Conclusions: In men, multimorbidity is associated with a reduced chance of advanced-stage 
oesophagogastric cancer, to levels seen collectively for women.
Key words: Cancer care/oncology, cancer epidemiology, doctor–patient relationship, electronic medical records, medical 
comorbidity, primary care
Introduction
Diagnosing cancer early is a UK government priority (1). By 2028, 
the target is for 75% of UK cancers to be diagnosed at an early 
stage, leading to 55  000 more people annually surviving 5  years 
post-diagnosis (1). Recognizing cancer symptoms and prompt inves-
tigation are key to achieving this.
In 2015–17, there were 15  800 annual diagnoses of oesopha-
geal (n = 9200) or stomach (n = 6600) cancers, with 12 300 deaths 
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(oesophagus, n  =  7900; stomach, n  =  4400) (2,3). Oesophageal 
and gastric cancers are generally considered together in diagnostic 
studies because they share symptoms and investigation pathways 
(4). Approximately two-thirds of diagnoses are in men (2,3). Women 
have a higher risk of emergency presentation and poorer 5- and 
10-year survival than men (5), although their 1-year survival is 
similar (2,3).
Around 50–60% of all cases are advanced-stage diagnoses (note 
incomplete staging data levels of 19% for oesophageal, 27% for 
stomach cancers), requiring more intense treatment, and with poorer 
outcomes (2,3). Diagnostic delay may contribute (6). Compared 
with rectal cancer, the odds of requiring three or more pre-referral 
primary-care consultations was higher for gastric [1.96, 95% con-
fidence interval (CI) 1.65–2.34] and oesophageal (1.15, 0.98–1.36) 
cancers (7). This suggests the potential for earlier investigation in 
the disease process. A shorter diagnostic interval (time from first re-
ported symptom to diagnosis) is associated with early-stage diag-
nosis of oesophageal cancer (8).
Patients with two or more pre-existing medical conditions (i.e. 
multimorbidity) may require complex management, with separate 
clinical pathways for each condition (9,10). This could expedite or 
delay diagnosis. Expedited diagnosis may occur in patients whose 
conditions require routine monitoring, by increasing opportunities 
for symptom reporting (the surveillance hypothesis) (11–13). In con-
trast, diagnosis may be delayed if cancer symptoms mimic those of 
the pre-existing condition (the alternative-explanations hypothesis) 
(13,14), or the primary-care consultations are dominated by condi-
tion management (the competing-demands hypothesis) (13).
Increased pre-existing condition count is associated with 
advanced-stage cancers of the ovary (15), larynx (16) and breast 
(12). In colorectal cancer, diagnostic intervals were longer by 32 days 
in patients with four or more conditions (17). Patients and clinicians 
may be more likely to normalize pre-existing symptoms, such as 
rectal bleeding, especially in patients with gastrointestinal condi-
tions (18). One study investigating pre-existing multimorbidity in 
nine cancers found an increased chance of advanced-stage diagnosis 
in those patients with three or more conditions (19). Patients with 
upper gastrointestinal cancer (liver/gastric) had the highest cancer-
specific index of multimorbidity (26%) of all nine cancers (19).
The impact of pre-existing conditions on the stage of 
oesophagogastric cancer at diagnosis is unknown. This study 
aimed to investigate whether oesophagogastric cancer stage is as-
sociated with: (i) pre-existing conditions that share symptoms of 
oesophagogastric cancer (‘alternative-explanations’ hypothesis) 
and (ii) multimorbidity (‘competing-demands’ or ‘surveillance’ 
hypotheses).
Methods
This retrospective cohort study of participants diagnosed with 
oesophagogastric cancer between 1 January 2010 and 31 December 
2015 was set in primary care in England. Data sources were the UK’s 
Clinical Practice Research Datalink (CPRD) GOLD database, with 
linkage to Public Health England’s National Cancer Registration 
and Analysis Service (NCRAS, set 15)  and Office for National 
Statistics (ONS) data. The CPRD holds anonymized longitudinal 
electronic records on symptoms, diagnoses, prescriptions and inves-
tigations of over 11.3 million patients from 674 UK general practices 
(20). Linked NCRAS data verified the date and type of diagnosis, 
and provided stage. Linked deprivation data (Townsend score) were 
obtained from ONS.
Inclusion and exclusion criteria
Participants were selected if they:
1. Were aged ≥40 years.
2. Had an incident oesophagogastric cancer code (International Clas-
sification of Diseases, version 10 codes C15, C16) in NCRAS be-
tween 1 January 2010 and 31 December 2015.
3. Had attended their GP at least once in the year before diagnosis.
Participants were excluded for missing NCRAS data on the best es-
timate of stage based on tumour size, nodal involvement and the 
presence of metastases (21).
Patient characteristics
Patient age and sex were provided by CPRD variables, assigning a 
birthday of 1 July. Patients were categorized from 1 (least deprived) 
to 5 (most deprived) using Townsend deprivation score data.
Stage and date at diagnosis
Stage at diagnosis was the outcome variable for regression analysis. 
Stage was classified as early (stage 1 or 2) or advanced (stage 3 or 
4) using the NCRAS staging variable. Diagnosis date was provided 
by NCRAS.
Features of possible oesophagogastric cancer 
before diagnosis
Participants’ CPRD records in the year before diagnosis were 
searched for codes for features of possible oesophagogastric 
cancer: dysphagia, dyspepsia, reflux, weight loss, upper abdom-
inal pain, nausea, vomiting, haematemesis and anaemia (4). 
Relevant Read code lists were assembled using an established 
protocol (22). Participant-level variables described the first pos-
sible feature of cancer (hereafter called ‘index feature’), with cat-
egory ‘0’ denoting asymptomatic status. The ‘index date’ was the 
date of the index feature, or the diagnosis date for asymptomatic 
participants.
Pre-existing conditions
Participant CPRD records before the index date were examined 
for medical codes for: (i) chronic conditions in the UK Quality and 
Outcomes Framework (QOF) (23); and (ii) conditions sharing symp-
toms with oesophagogastric cancer (selected by MQ, MC and WH) 
(Table 1).
Key Messages
• First study of association between multimorbidity and oesophagogastric cancer stage.
• In men, multimorbidity is associated with reduced chance of advanced stage.
• This study could not investigate the mechanism of this association.
• Having diagnostic alternatives for cancer symptoms was not associated with stage.
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The QOF conditions were: anxiety and/or depression; asthma; 
atrial fibrillation; chronic obstructive pulmonary disease; coronary 
heart disease; dementia; diabetes mellitus; epilepsy; heart failure; 
high blood pressure; hypothyroidism; learning disability; mental 
health disorders (bipolar disorder, schizophrenia and other psych-
oses); osteoporosis; peripheral arterial disease and rheumatoid 
arthritis.
Explanatory variables denoting multimorbidity and 
alternative explanations
Participant-level indicator variables identified participants with two 
or more pre-existing conditions (i.e. multimorbidity) before the 
index date. The numbers (percentages) of participants (by sex) with 
each pre-existing condition are reported.
Participant-level indicator variables denoting ‘alternative explan-
ations’ identified participants with one or more pre-existing condi-
tions that provided a plausible explanation for their index feature(s).
Data analysis
The cohort is summarized using descriptive statistics. The numbers 
with each comorbid condition and with alternative explanations are 
reported by sex, for all participants included in analysis or excluded 
for missing stage. Associations with sex were explored using the 
chi-square test.
Associations between stage at diagnosis (reference group: early 
stage) and both multimorbidity (reference group: no multimorbidity) 
and the presence of alternative explanations (reference group: no al-
ternative explanations) were analysed using multi-level logistic re-
gression. Interaction terms were sought on clinical grounds between 
sex and: (i) multimorbidity, and (ii) the presence of an alternative 
explanation; and (iii) between multimorbidity and age. The analyses 
accounted for the correlation among individuals within the same 
general practices (clusters) and adjusted for possible confounding by 
age at diagnosis, sex, deprivation and cancer site. Robust standard 
errors accounted for heteroscedasticity and the analysis was re-
peated with log(age) and with age-squared to check for non-linearity. 
Post-estimation diagnostics tested for model specification (linktest), 
goodness of fit (lfit) and collinearity between explanatory variables 
(collin, Collinearity Diagnostics, Philip B Ender, UCLA Office of 
Academic Computing).
The regression coefficients are presented. To ease interpretation, 
after running the final model, we used Stata’s margins commands to 
estimate the predicted probability of having an advanced-stage diag-
nosis for the following groups of interest, holding other variables to 
their mean values:
1. Men and women with multimorbidity.
2. Men and women with alternative explanations.
Data analysis was conducted using Stata (version 16)  (StataCorp, 
College Station, TX).
Missing data, bias and sensitivity analysis
Both CPRD and NCRAS have missing data. In line with convention, 
we interpreted the absence of a code for a clinical event as its non-
occurrence (14,20,24). We classified participants with no recorded 
features of cancer and/or no diagnostic codes for comorbid condi-
tions as not presenting with alternative explanations.
To examine for bias, we conducted a logistic regression to com-
pare participants with and without staging data with regard to the 
explanatory variables for our main model, including interaction 
terms between multimorbidity and age or sex.
In sensitivity analysis, we re-ran the final model, including par-
ticipants with missing staging data assigned to advanced-stage 
diagnosis.
Power calculation
The complete-case sample of 1749 patients had >95% power to 
detect a change of 10 percentage points in the proportion diag-
nosed with advanced disease between those with and without 
multimorbidity (two-sided, alpha = 0.01). This is based on 60% of 
participants being multimorbid and 70% having advanced-stage 
disease (9,10).
Results
The NCRAS-linked CPRD GOLD dataset provided 2444 parti-
cipants meeting the inclusion criteria (Table  2). Six hundred and 
ninety-five (28.4%) participants (n = 268, 38.6% female) were ex-
cluded for missing stage (Fig. 1), leaving 1749 (513 female, 29.3%) 
participants (oesophagus: n  =  1089, 62.3%; stomach: n  =  660, 
37.7%) in the analysis. The mean age at diagnosis was 69.2 (SD 
10.4) years for men and 72.4 (12.2) years for women. The mean 
(SD) age of excluded participants was 75.4 (12.0) years [male: 73.3 
(11.3) years, n = 427; female: 78.9 (12.3) years, n = 268]. The me-
dian time from index date to diagnosis date was 24 days (interquar-
tile range 6–89 days).
Index features of cancer
Most included participants (1387/1749, 79.3%) had recorded fea-
tures of possible oesophagogastric cancer before diagnosis (Table 2). 
Dysphagia was most common in men (324/1236, 26.2%) and 
women (159/513, 31.0%). Dyspepsia and/or reflux was the next 
most common (men: 231/1236, 18.7%; women: 83/513, 16.8%), 
followed by anaemia (194/1236, 15.7%; 69/513, 13.5%) and upper 
abdominal pain (143/1236, 11.6%; 63/513, 12.3%). Weight loss 
(50/1236, 4.0%; 18/513, 3.5%), vomiting (25/1236, 2.0%; 44/513, 
8.6%), nausea (42/1236, 3.4%; 12/513, 2.3%) and haematemesis 
(11/1236, 0.9%; 1/513, 0.2%) were relatively infrequent.
A similar proportion of excluded participants (532/695, 
76.6%) had pre-diagnostic features of oesophagogastric cancer (see 
Supplementary Material).
Table 1. Conditions providing alternative diagnostic explanations for features of possible oesophageal cancer
Feature of possible oesophageal cancer Condition providing an alternative diagnostic explanation for the feature
Dysphagia Parkinson’s disease, oesophageal stricture and stroke (also a QOF condition)
Weight loss and anaemia Inflammatory bowel disease and chronic kidney disease (also a QOF condition)
Nausea, vomiting and upper abdominal pain Hernia, pancreatitis, ulcer, gastritis, oesophagitis and irritable bowel syndrome
Haematemesis Anticoagulant medications (note, the need for anticoagulation was treated as a ‘condition’)
Dyspepsia/reflux Oesophagitis, gastritis














Most participants in the analysis (1136/1749, 65.0%) were classi-
fied as multimorbid before the index date: 344/484 (71.1%) in those 
with early-stage and 792/1265 (62.6%) in advanced-stage disease 
(Table 2). The most common conditions were hypertension (43.5% 
in men, 45.6% in women) and being on anticoagulant medication 
(43.3% men, 39.0% women) (see Table 3). Most conditions had an 
even sex distribution, with some exceptions of conditions predom-
inant in women; notably, anxiety/depression (21.6% in men, 36.8% 
in women), hypothyroidism (4.1% in men, 15.8% in women), osteo-
porosis (1.1% in men, 12.1% in women) and irritable bowel syn-
drome (4.0% in men, 9.9% in women).
The majority of participants excluded for missing stage were 
classified as multimorbid (490/695, 70.5%) (Table 3).
Alternative explanations
Alternative explanations for index features of cancer occurred in 
280/1749 (16.0%) included participants (123/695, 17.7% excluded 
participants), with similar patterns in men and women. The most 
common combinations were alternative explanations for nausea, 
vomiting or upper abdominal pain (included participants: 92/1749, 
5.3%; excluded participants: 45/695, 6.5%), for weight loss or an-
aemia (88/1749, 5.0%; 46/695, 6.6%) and for dyspepsia/reflux 
(56/1749, 3.2%; 14/695, 2.0%).
Stage at diagnosis
Advanced-stage oesophagogastric cancer was diagnosed in 
1265/1749 (72.3%) of included participants (909/1236, 73.5% 
for men; 356/513, 69.4% for women). The proportion with 
multimorbidity was higher in those with early-stage (71.1%) 
than with advanced-stage (62.6%) disease. The proportions with 
alternative explanations for their index features of cancer were 
similar in patients with early or with advanced-stage disease 
(Table 2).
Regression analyses
In univariable analyses, multimorbidity (odds ratio 0.68, 95% 
CI 0.55–0.85, P  =  0.001) and age at diagnosis (0.98, 0.97–
0.99, P  <  0.0001) were associated with stage at diagnosis. In 
multivariable analyses, there was moderate evidence of an inter-
action term between sex and multimorbidity (odds ratio 1.76, 
95% CI 1.08–2.86, P  = 0.024, Table 4), controlling for age, de-
privation and cancer site.
No interaction terms were found between age and multimorbidity 
(1.00, 0.98–1.02, P = 0.682) or between sex and alternative explan-
ations (1.69, 0.64–2.12, P = 0.608).
Post-estimation margins commands on the final model re-
ported the probability of advanced-stage diagnosis to be similar 
in women with (0.71, 0.66–0.75, P  <  0.0001, n  =  353) or 
without (0.69, 0.62–0.76, P < 0.0001, n = 160) multimorbidity. 
The probability of advanced-stage diagnosis in men was lower 
for those with multimorbidity (0.70, 0.67–0.74, P  <  0.0001, 
n  =  783) than in those without (0.79, 0.75–0.83, P  <  0.0001, 
n = 453).
Having alternative explanations was not associated with stage 
(Table 4). Consequently, the probabilities of advanced-stage disease 
were similar in people with (0.74, 0.69–0.78) and without (0.72, 
0.70–0.75) alternative explanations.
Post-estimation regression diagnostics suggested no problems in 
model specification, goodness of fit or collinearity between explana-
tory variables (results available from authors).
Table 2. Characteristics of study participants (included or excluded for missing stage)
Covariate Included in analysis (N = 1749) Excluded for missing stage (N = 695)
Early stage Advanced stage Total in analysis
N (%) 484 (27.7) 1265 (72.3) 1749 695
Female, n (%) 157 (32.4) 356 (28.1) 513 (29.3) 268 (38.6)
Age, mean (SD) 71.8 (10.9) 69.5 (11.1) 70.1 (11.1) 75.4 (12.0)
Site
 Oesophagus, n (%) 285 (58.9) 804 (63.6) 1089 (62.3) 394 (56.7)
 Stomach, n (%) 199 (41.1) 461 (36.4) 660 (37.7) 301 (43.3)
Townsend quintile, mean (SD) 2.8 (1.3) 2.9 (1.3) 2.9 (1.3) 2.8 (1.3)
Presented with feature of possible cancer, n (%) 374 (77.3) 1013 (80.1) 1387 (79.3) 532 (76.6)
Multimorbidity, n (%) 344 (71.1) 792 (62.6) 1136 (65.0) 490 (70.5)
Alternative explanation, n (%) 81 (16.7) 199 (15.7) 280 (16.0) 123 (17.7)
Participants were aged ≥40 years and had attended their CPRD general practice at least once in the year before their incident diagnosis with oesophagogastric 
cancer in the period 1 January 2010 to 31 December 2015. Participants with features of possible cancer presented with any of dysphagia, dyspepsia and/or reflux, 
weight loss, upper abdominal pain, nausea, vomiting, haematemesis or anaemia in the year before diagnosis. Multimorbidity was defined as having at least two 
conditions diagnosed before either the first possible feature of cancer or cancer diagnosis (for participants who did not present with cancer features). Participants 
with alternative explanations had pre-existing conditions providing a plausible diagnostic alternative for their cancer feature.
Figure 1. Exclusion criteria.
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Missing data and sensitivity analyses
In logistic regression comparing patients with and without staging 
data, missingness was associated with increasing age (1.04, 95% 
CI 1.03–1.05, P < 0.0001) and with being female (1.28, 1.06–1.55, 
P = 0.01). We found no interactions between multimorbidity and age 
(interaction term: 1.02, 95% CI 0.99–1.04, P = 0.12) or sex (1.28, 
0.85–1.90, P = 0.251).
In ‘missing-is-advanced-stage’ analysis, the coefficients were 
similar to those in the main model, apart from age (1.00, 95% CI 
0.99–1.01, P = 0.683) (see Supplementary Material).
Discussion
Summary
This is the first primary-care study to examine the association between 
pre-existing medical conditions and the stage of oesophagogastric 
cancer at diagnosis. We provide some evidence of differing effects of 
multimorbidity between the sexes. For men, being multimorbid reduces 
the chance of advanced-stage oesophagogastric cancer to levels seen for 
women regardless of their multimorbidity status, controlling for age, 
deprivation and cancer site. Having alternative explanations for fea-
tures of possible oesophagogastric cancer is not associated with stage.
Strengths and limitations
The study analysed 1749 primary care patients in England, ensuring 
ample power. Our data source was the CPRD, which has NCRAS 
linkage, and is large and representative, enabling generalizability 
of our results (20). The demographics of our sample are consistent 
with the epidemiology of oesophagogastric cancer, in terms of age 
at diagnosis, sex and deprivation profiles, and unknown stage (2,3). 
A further strength is the primary-care setting, where general practi-
tioners face the difficulty of recognizing which patients need referral 
or investigation for undiagnosed cancer.
Our main limitations relate to missing CPRD and NCRAS data. 
First, when using CPRD data, we depend on how GPs choose which 
clinical details to record and their recording method. Our use of QOF 
conditions likely minimizes any underestimation of multimorbidity, 
as QOF conditions are well-defined and coded recording is en-
couraged by linkage to practice payments (23). Test results have 
automated transmission, with have low levels of missingness (20). 
However, some symptoms may have been omitted, or recorded in 
the ‘free-text’ section—which is inaccessible to researchers. For 
vague symptoms especially, up to one-third of affected participants 
may have symptom records ‘lost’ in free text (25). Symptom under-
recording may arise because of time-pressured consultations, cogni-
tive factors influencing clinical assessment and diagnostic reasoning 
(26,27). We may have underestimated the numbers with alternative 
explanations, reducing our power to identify associations between 
alternative explanations and stage.
Our study is limited by having to exclude 695 (28.4%) of 
the sample with no recorded stage. Incomplete staging data for 
oesophagogastric cancer is a known issue (2,3). Stage was plaus-
ibly missing at random, conditional on increasing age and female 
sex. This is consistent with patients who are elderly or who present 
as an emergency (more likely in women) having less comprehensive 
Table 3. Numbers (%) of males and females with each comorbidity
Comorbidity With staging data Missing staging data
Males, n  
(% of 1236  
males in analysis)
Females, n  
(% of 513  
females in analysis)
P value Males, n  
(% of 427 excluded 
from analysis)
Females, n  
(% of 268 excluded  
from analysis)
P value
Anticoagulants 535 (43.3) 200 (39.0) 0.097 216 (50.6) 133 (49.6) 0.806
Anxiety/depression 267 (21.6) 189 (36.8) <0.0001 83 (19.4) 89 (33.2) <0.0001
Asthma 126 (10.2) 64 (12.5) 0.163 39 (9.1) 32 (11.9) 0.234
Atrial fibrillation 82 (6.6) 35 (6.8) 0.886 43 (10.1) 31 (11.6) 0.533
CHD 227 (18.4) 66 (12.9) 0.005 79 (18.5) 32 (11.9) 0.022
CKD 174 (14.1) 94 (18.3) 0.025 68 (15.9) 63 (23.5) 0.013
COPD 113 (9.1) 38 (7.4) 0.240 47 (11.0) 25 (9.3) 0.480
Diabetes 219 (17.7) 54 (10.5) <0.0001 84 (19.7) 37 (13.8) 0.047
Gastritis/oesophagitis 225 (18.2) 95 (18.5) 0.877 66 (15.5) 48 (17.9) 0.395
Heart failure 44 (3.6) 21 (4.1) 0.591 22 (5.2) 17 (6.3) 0.507
Hernia 98 (7.9) 62 (12.1) 0.006 31 (7.3) 36 (13.4) 0.007
Hypertension 538 (43.5) 234 (45.6) 0.424 191 (44.7) 148 (55.2) 0.007
Hypothyroidism 50 (4.1) 81 (15.8) <0.0001 19 (4.5) 40 (14.9) <0.0001
IBD 68 (5.5) 34 (6.6) 0.360 17 (4.0) 14 (5.2) 0.440
IBS 49 (4.0) 51 (9.9) <0.0001 12 (2.8) 21 (7.8) 0.002
Osteoporosis 13 (1.1) 62 (12.1) <0.0001 11 (2.6) 39 (14.6) <0.0001
Peripheral arterial disease 62 (5.0) 18 (3.5) 0.170 35 (8.2) 17 (6.3) 0.366
Rheumatoid arthritis 21 (1.7) 18 (3.5) 0.020 5 (1.2) 6 (2.2) 0.272
Schizophrenia, bipolar 
disorder, other psychoses
16 (1.3) 2 (0.4) 0.088 4 (0.9) 8 (3.0) 0.044
Stroke 113 (9.1) 44 (8.6) 0.706 42 (9.8) 26 (9.7) 0.954
Ulcer 76 (6.2) 16 (3.1) 0.010 33 (7.7) 14 (5.2) 0.201
Other 48 (3.9) 22 (4.3) 0.694 30 (7.0) 31 (11.6) 0.039
CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease; IBS, irritable 
bowel syndrome. Other conditions in men and women, respectively: epilepsy (n = 27, n = 7); dementia (n = 10, n = 10); Parkinson’s (n = 4, n = 1); pancreatitis 
(n = 1, n = 1); oesophageal stricture (n = 2 men); learning disability (n = 4, n = 3).
P values are from chi-square tests. Gender differences for participants included in analysis highlighted in bold.
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diagnostic and staging investigations (13,28,29). It is reassuring that 
the distributions of age and sex in our sample included in the ana-
lyses are very similar to national figures (2,3), suggesting that any 
bias was small. Furthermore, in sensitivity ‘missing-is-advanced’ 
analyses, the coefficients for multimorbidity, sex and their inter-
action were similar in size to those in the main model.
Comparison with previous literature
Previous research established associations between multimorbidity 
and advanced-stage diagnosis of ovarian, laryngeal, breast and colo-
rectal cancers (12,14–16). Findings related to gastric/liver cancers were 
inconclusive, although separate effects for gastric and liver cancers or 
for men and women were not investigated (19). Our findings are con-
sistent with the surveillance hypothesis effect of multimorbidity in 
oesophagogastric cancer for men (7,13). Men consult primary care 
less frequently than women, after allowing for women’s consultations 
for reproductive health care; however, the difference was not observed 
between men and women with comparable morbidities (30).
We found no association between stage and having alternative 
explanations; therefore, our study does not elucidate why women 
are more likely than men to be diagnosed following an emergency 
presentation (2,3,5).
Our findings contrast with our previous study of bladder cancer 
(14). For that cancer, we found no association between count of 
pre-existing conditions and stage, but a strong association between 
alternative explanations for features of bladder cancer and advanced-
stage diagnosis (14). This difference may reflect the symptomatology 
of the two cancers: haematuria is the dominant symptom and highly 
predictive of bladder cancer (14,31), and is recommended for ur-
gent investigation (4). In contrast, in our study, less than one-third 
of oesophageal cancers presented with the high-risk symptom of dys-
phagia, the majority presenting with low-risk features. It may be that 
the increased primary-care attendances trigger investigation of low-
risk symptoms, such as dyspepsia, though not necessarily with cancer 
as the condition being sought. There is a clear relationship between a 
primary-care practice’s increased gastroscopy rates and improved oe-
sophageal cancer outcomes, supporting this interpretation (32).
Implications for research and practice
This study is consistent with the surveillance hypothesis, at least 
in men. It has always been considered good primary-care practice 
to extend the consultation beyond the presenting complaint, by 
elucidating other concerns, offering health care advice and pre-
ventative care. These ‘supplementary’ aspects require time, which 
is not always available within a single consultation. This study 
cannot provide a definite mechanism for the findings, being ob-
servational, but suggests that extra patient contact may have a 
measureable benefit. Further planned research will explore pos-
sible mechanisms by investigating gender differences in the rec-
ognition of cancer symptoms, and assessment of cancer risk in 
multimorbidity.
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Table 4. Logistic regression analyses of stage at diagnosis (early versus advanced), reporting odds ratios (95% CIs) for unadjusted and 
adjusted analyses
Covariate Unadjusted (univariable analysis) Adjusted (multivariable analysis)
OR (95% CI) P value OR (95% CI) P value
Multimorbidity 0.68 (0.55–0.85) 0.001 0.63 (0.47–0.85) 0.002
Sex 0.82 (0.65–1.03) 0.083 0.59 (0.39–0.89) 0.011
Interaction term (multimorbidity × sex) n/a n/a 1.76 (1.08–2.86) 0.024
Has an ‘alternative explanation’ 0.93 (0.70–1.22) 0.600 1.07 (0.80–1.43) 0.631
Cancer site 1.22 (1.00–1.50) 0.068 1.21 (0.97–1.50) 0.090
Age at diagnosis 0.98 (0.97–0.99) <0.0001 0.99 (0.98–0.99) 0.004
Deprivation quintile 1.03 (0.96–1.11) 0.399 1.04 (0.96–1.13) 0.304
Multimorbidity was defined as ≥2 pre-existing conditions. Participants with ‘alternative explanations’ had a pre-existing condition that provided a plausible 
diagnostic alternative for their presenting feature of oesophagogastric cancer (i.e. dysphagia, dyspepsia and/or reflux, weight loss, upper abdominal pain, nausea, 
vomiting, haematemesis or anaemia). Note: Odds ratios (ORs) >1 indicate increased odds of advanced stage at diagnosis and ORs <1 indicate reduced odds. An 
‘alternative explanation’ is a condition that provides a plausible diagnostic alternative for the index cancer symptom (reference group: no alternative explanation). 
Multimorbidity is defined as two or more pre-existing conditions (reference group: not multimorbid). For sex, the reference group is men.
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